Abstract
Background and Objective
SUBA-itraconazole and Sporanox are two oral formulations of itraconazole. Drug–drug interactions with omeprazole have been previously reported; however, mechanistic understanding of the pharmacological and physiological interactions of omeprazole with orally administered itraconazole within a population modeling paradigm is lacking. The objective of this analysis was to mechanistically describe and quantify the effect of omeprazole on the pharmacokinetics of itraconazole and its major metabolite, hydroxyitraconazole from the SUBA itraconazole and Sporanox formulations.
Methods
An in vitro–in vivo (IVIV) pharmacokinetic model of itraconazole and hydroxyitraconazole was developed including data from an omeprazole interaction study with SUBA itraconazole. Meta-models of gastric pH for healthy subjects and subjects receiving omeprazole were integrated into the IVIV model to capture omeprazole-mediated gastric pH changes on itraconazole dissolution and absorption.
Results
Omeprazole influenced the kinetics of itraconazole through altering the dissolution and absorption due to the pH-dependent solubility of itraconazole, inhibition of efflux transporters, and inhibiting the metabolism of itraconazole and hydroxyitraconazole. The model-predicted population effects of omeprazole on itraconazole from SUBA-itraconazole were to increase the area under the concentration–time curve (AUC0–24) and maximum concentration (Cmax) by 35 and 31%, respectively, and to decrease AUC0–24 and Cmax from Sporanox by 68 and 76%, respectively.
Conclusion
Unlike SUBA itraconazole, which requires basic pH for itraconazole release, the omeprazole-induced pH-mediated reduction in Sporanox dissolution overrides any increased exposure from the drug–drug interaction at hepatic metabolizing enzymes or efflux transporters. The model presented here is the most complete quantitative description of the pharmacokinetics of itraconazole and hydroxyitraconazole currently available.
Similar content being viewed by others
References
Grant SM, Clissold SP. Itraconazole: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in superfecial and systemic mycoses. Drugs. 1989;37(3):310–44.
Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev. 2002;34(1–2):47–54.
Abuhelwa AY, Mudge S, Hayes D, Upton RN, Foster DJ. Population in vitro–in vivo correlation model linking gastrointestinal transit time, pH, and pharmacokinetics: itraconazole as a model drug. Pharm Res. 2016;33(7):1782–94.
Abuhelwa AY, Foster DJ, Mudge S, Hayes D, Upton RN. Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states. Antimicrob Agents Chemother. 2015;59(9):5681–96.
Abuhelwa AY, Mudge S, Upton RN, Foster DJR. Population in vitro–in vivo pharmacokinetic model of first-pass metabolism: itraconazole and hydroxy-itraconazole. J Pharmacokinet Pharmacodyn. 2018;45(2):181–97.
Abuhelwa AY, Foster DJ, Upton RN. A quantitative review and meta-models of the variability and factors affecting oral drug absorption-part I: gastrointestinal pH. AAPS J. 2016;18(5):1309–21.
Abuhelwa AY, Foster DJ, Upton RN. A quantitative review and meta-models of the variability and factors affecting oral drug absorption-part II: gastrointestinal transit time. AAPS J. 2016;18(5):1322–33.
Wilde MI, McTavish D. Omeprazole: an update of its pharmacology and therapeutic use in acid-related disorders. Drugs. 1994;48(1):91–132.
Rang H, Dale M, Ritter J, Flower R, Henderson G. Rang and Dale’s Pharmacology 6th. London: Elsevier Co; 2007.
Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol. 2001;364(6):551–7.
Li W, Zeng S, Yu L-S, Zhou Q. Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management. Ther Clin Risk Manag. 2013;9:259.
Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet. 2010;49(8):509–33.
European Medicines Agency (EMEA). Note for guidance on good clinical practice (CPMP/ICH/135/95). Step 5: consolidated guideline, including post step 4 errata. London: EMEA; 1996.
World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA. 1997;277(11):925–6.
Beal S, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM user’s guides, Part V. (1989–2009). Ellicott City: Icon Development Solutions; 2009.
Holford, N.: Wings for NONMEM Version 7.30 for NONMEM 7.3. 2015. (2015)
Core Team R. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2014.
Wickham H. ggplot2: elegant graphics for data analysis. New York: Springer; 2009.
Wickham H. plyr—the split-apply-combine strategy for data analysis. J Stat Softw. 2011;40(1):1–29.
Wickham H. Scales: scale functions for graphics. 2014. http://CRAN.R-project.org/package=scales
Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models. I. models for covariate effects. J Pharmacokinet Biopharm. 1992;20(5):511–28.
Gan K, Geus W, Lamers C, Heijerman H. Effect of omeprazole 40 mg once daily on intraduodenal and intragastric pH in H. pylori-negative healthy subjects. Dig Dis Sci. 1997;42(11):2304–9.
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14(1):135.
Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol. 1997;37(6):486–95.
Naidu M, Shobha J, Dixit V, Kumar A, Kumar TR, Sekhar KR, et al. Effect of multiple dose omeprazole on the pharmacokinetics of carbamazepine. Drug Invest. 1994;7(1):8–12.
Christians U, Schmidt G, Bader A, Lampen A, Schottmann R, Linck A, et al. Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol. 1996;41(3):187–90.
Maguire M, Franz T, Hains DS. A clinically significant interaction between tacrolimus and multiple proton pump inhibitors in a kidney transplant recipient. Pediatr Transplant. 2012;16(6):E217–20.
Collett A, Tanianis-Hughes J, Carlson GL, Harwood MD, Warhurst G. Comparison of P-glycoprotein-mediated drug–digoxin interactions in Caco-2 with human and rodent intestine: relevance to in vivo prediction. Eur J Pharm Sci. 2005;26(5):386–93.
Oosterhuis B, Jonkman J, Andersson T, Zuiderwijk P, Jedema J. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br J Clin Pharmacol. 1991;32(5):569–72.
Jaruratanasirikul S, Sriwiriyajan S. Effect of omeprazole on the pharmacokinetics of itraconazole. Eur J Clin Pharmacol. 1998;54(2):159–61.
Lohitnavy M, Lohitnavy O, Thangkeattiyanon O, Srichai W. Reduced oral itraconazole bioavailability by antacid suspension. J Clin Pharm Ther. 2005;30(3):201–6.
Acknowledgements
AYA is supported at the School of Pharmacy and Medical Sciences at the University of South Australia by a Science and Industry Endowment Fund STEM + Business Fellowship of the Commonwealth Scientific and Industrial Research Organisation. The Australian Centre for Pharmacometrics is an initiative of the Australian Government as part of the National Collaborative Research Infrastructure Strategy.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
All pharmacokinetic studies of Sporanox and SUBA-itraconazole used in the analysis were sponsored by Mayne Pharma International, Salisbury South, South Australia, Australia.
Conflict of Interest
SM is an employee at Mayne Pharma. DJRF, RNU and AYA have acted as paid consultants for Mayne Pharma International, Salisbury South, South Australia, Australia.
Ethical Approval
All oral pharmacokinetic studies were conducted by Mayne Pharma International, Salisbury South, South Australia, Australia, in accordance with the ICH Guidelines for Good Clinical Practice, the Declaration of Helsinki on the ethical conduct of medical research, and applicable regulatory requirements.
Informed Consent
Each subject provided written informed consent before study participation.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Abuhelwa, A.Y., Mudge, S., Upton, R.N. et al. Mechanistic Assessment of the Effect of Omeprazole on the In Vivo Pharmacokinetics of Itraconazole in Healthy Volunteers. Eur J Drug Metab Pharmacokinet 44, 201–215 (2019). https://doi.org/10.1007/s13318-018-0519-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13318-018-0519-1